ClinicalTrials.gg
CompletedNCT01432236Updated Jan 22, 2021Results posted

A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression

A Phase 3 interventional study of Pregabalin and placebo in Fibromyalgia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 37 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-22.

Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
197
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing pregabalin in Fibromyalgia — 6 open to participants now, 6 under way, none of them phase 3. Pregabalin · Fibromyalgia.

Enrollment
16th of 30
197 · median 199
Started
2011
with 3 others
Phase 3
13 of 30
none open now
Registered
19th of 30
by date
Lead sponsor
15 of 30
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Among the 30 studies testing pregabalin in Fibromyalgia, this one is the 16th largest by enrollment, is one of 4 that started in 2011, is one of 13 in phase 3, and was the 19th registered.

Fibromyalgia

1,244 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.

Browse Fibromyalgia studies →

Open to participants now

6 of the 30 studies testing pregabalin in Fibromyalgia are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About pregabalin

Pregabalin: first FDA approval 2004 (LYRICA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 161 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 97 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing pregabalin in Fibromyalgia, or all of them as a file.
02

Study summary

The intent of this study is to identify and treat fibromyalgia subjects with comorbid depression who are receiving an SSRI (selective serotonin reuptake inhibitor) or SNRI (selective norepinephrine reuptake inhibitor) primarily for their depression and to determine whether pregabalin demonstrates improvement relative to placebo in improving pain associated with fibromyalgia.

03

Conditions studied

  • Fibromyalgia

Keywords

  • Pregabalin
  • Lyrica
  • depression
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women of any race or ethnicity who are at least 18 years of age.
  • Adult women and men with a diagnosis of fibromyalgia and stable depression (major depressive disorder, depression not otherwise specified (NOS), or dysthymia) who have been taking an antidepressant (SSRI or SNRI) primarily for their depression for at least 3 months.

Exclusion criteria

Exclusion Criteria:

  • Have failed pregabalin treatment due to lack of improvement of symptoms at doses of greater than or equal to 300 mg daily, cannot tolerate pregabalin or any pregabalin ingredient, or participated in a pregabalin clinical trial. If the subject has taken pregabalin and discontinued for reason other than lack of improvement or intolerance, then they will be eligible. Pregabalin use within the last 30 days (prior to V1) is not permitted.
  • Patients with severe or unstable depression are not eligible.
  • Patients with other types of pain or conditions that may make it difficult to evaluate fibromyalgia symptoms are not eligible
  • Any subject considered at risk of suicide or self harm based on investigator judgment and/or the details of a risk assessment
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
197 participants (actual)

Study arms

  • Experimental
    Pregabalin

    Group 1 as Pregabalin vs. Placebo (cross over study in which period one has this group)

    Drug: Pregabalin

  • Placebo comparator
    Placebo

    Group 2 as placebo vs. pregabalin (cross over study in which period two will have this group)

    Drug: placebo

Interventions

  • Pregabalin 300 or 450 mg/day dosed BID ( twice a day) for 14 weeks; 150 mg/day starting dose

  • Drugplacebo

    placebo capsules twice a day for 14 weeks

06

What researchers measure

Primary outcomes

  1. Mean NRS Pain Score at End of Period.

    The daily pain diary consists of an 11-point numeric scale (NRS) ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants describe their pain during the past 24 hours by choosing the appropriate number between 0 and 10. The endpoint mean pain scores for Period 1 and Period 2 are defined as the mean of the last 7 non-missing daily diary pain ratings while taking study medication in the double-blind phase during Period 1 and Period 2, respectively.

    Time frame: End of each period, at Weeks 6 and 14

Secondary outcomes

  1. Fibromyalgia Impact Questionnaire (FIQ) Score at Baseline.

    This was a 20-item participant reported outcome instrument. It contained 10 subscales, which were combined to yield a total score. The first 11 questions were related specifically to physical functioning subscale, ranging from 0 to 10. The remaining 9 questions assessed pain, fatigue, stiffness, difficulty working, and symptoms of anxiety and depression ranging from 0 to 10. The higher values indicated greater impairment. All 20 were combined to form a total score ranging from 0 to 100, provides an estimation of fibromyalgia impact with higher scores indicating more impairment. The severity categorizations for the FIQ are: less than 40 (mild), 40-60 (moderate), and above 60 (severe).

    Time frame: Baseline

  2. FIQ Score at End of Period.

    This was a 20-item participant reported outcome instrument. It contained 10 subscales, which were combined to yield a total score. The first 11 questions were related specifically to physical functioning subscale, ranging from 0 to 10. The remaining 9 questions assessed pain, fatigue, stiffness, difficulty working, and symptoms of anxiety and depression ranging from 0 to 10. The higher values indicated greater impairment. All 20 were combined to form a total score ranging from 0 to 100, provides an estimation of fibromyalgia impact with higher scores indicating more impairment. The severity categorizations for the FIQ are: less than 40 (mild), 40-60 (moderate), and above 60 (severe).

    Time frame: End of each period, at Weeks 6 and 14

  3. Patient Global Impression of Change (PGIC) at the End of Period 1.

    PGIC: participant rated instrument to measure participant's change in overall status on a 7-point scale; range from 1 (very much improved) to 7 (very much worse).

    Time frame: End of Period 1 at Week 6

  4. Percentage of Participants With >=30% and >=50% Pain Reduction Based on Daily Pain Diary.

    Participant with at least a 30% reduction in mean pain score from baseline (at randomization) to the endpoint at the end of each period (Visits 6 and 12) is considered a 30% responder, for the respective period. Similarly, a subject with at least a 50% reduction in mean pain score from baseline (at randomization) to the endpoint at the end of each period (Visits 6 and 12) is considered a 50% responder, for the respective period.

    Time frame: Visits 2, 6, and 12

  5. Subjective Sleep Questionnaire - Mean Sleep Quality at End of Period.

    Subjective Sleep Questionnaire included 5 items: participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night. Subjective rating of quality of sleep during the past night was done by selecting a number between 0 (very poor) and 10 (excellent). Mean sleep quality was calculated as the mean of the last seven days, the potential range of responses was therefore 0-10.

    Time frame: End of each period, at Weeks 6 and 14

  6. Subjective Sleep Questionnaire - Mean Subjective Wake After Sleep Onset at End of Period.

    Subjective Sleep Questionnaire included, participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (numeric rating scale) for the previous night. Subjective wake after sleep onset was the subjective estimate of the total amount of time the participant was awake after initial sleep onset until final awakening.

    Time frame: End of each period, at Weeks 6 and 14

  7. Subjective Sleep Questionnaire - Mean Latency to Sleep Onset at End of Period.

    Subjective Sleep Questionnaire included, participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (numeric rating scale) for the previous night. Subjective latency to sleep onset was the subjective estimate of the amount of time to fall asleep after lights out.

    Time frame: End of each period, at Weeks 6 and 14

  8. Subjective Sleep Questionnaire - Mean Subjective Total Sleep Time at End of Period.

    Subjective Sleep Questionnaire included, participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (numeric rating scale) for the previous night. Subjective total sleep time was the subjective estimate of the total amount of time the participant was asleep after lights out until final awakening.

    Time frame: End of each period, at Weeks 6 and 14

  9. Subjective Sleep Questionnaire - Parameter Estimates for Subjective Number of Awakenings Per Night After Sleep Onset at End of Period.

    Subjective Sleep Questionnaire included, participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (numeric rating scale) for the previous night. Subjective number of awakenings after sleep onset was the subjective estimate of the total number of times the participant awakened during the night until final awakening.

    Time frame: End of each period, at Weeks 6 and 14

  10. Hospital Anxiety and Depression Scale (HADS) at Baseline.

    HADS: participant rated questionnaire with 2 subscales. HADS-A (anxiety) assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D (depression) assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.

    Time frame: Baseline

  11. HADS at End of Period.

    HADS: participant rated questionnaire with 2 subscales. HADS-A (anxiety) assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D (depression) assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.

    Time frame: End of each period, at Weeks 6 and 14

  12. Mean EuroQoL 5-Dimensions (EQ-5D) Score at Baseline.

    EQ-5D is a standardized, participant-administered measure of health outcome. It provides a descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), using 3 levels (no, moderate, or extreme problems) and a single index value characterizing current health status using a 100-point visual analog scale (0=worst, 100=best). EQ-5D summary index is obtained with a formula that weights each level of the dimensions. The index-based score is interpreted along a continuum of 0 (death) to 1 (perfect health).

    Time frame: Baseline

  13. EQ-5D Score at End of Period.

    EQ-5D is a standardized, participant-administered measure of health outcome. It provides a descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), using 3 levels (no, moderate, or extreme problems) and a single index value characterizing current health status using a 100-point visual analog scale (0=worst, 100=best). EQ-5D summary index is obtained with a formula that weights each level of the dimensions. The index-based score is interpreted along a continuum of 0 (death) to 1 (perfect health).

    Time frame: End of each period, at Weeks 6 and 14

Other outcomes

  1. PGIC at the End of Period 2.

    PGIC: participant rated instrument to measure participant's change in overall status on a 7-point scale; range from 1 (very much improved) to 7 (very much worse). Because of the crossover design and PGIC recall period (since starting study medication), the Period 1 PGIC data were felt to provide the clearest comparison across treatments, whereas Period 2 PGIC data were felt to have a more complex interpretation. Thus PGIC at End of Period 2 was separately analyzed from PGIC at End of Period 1.

    Time frame: End of Period 2 at Week 14

  2. Mean Patient Static Global Assessment (PSGA) Score at Baseline.

    PSGA was a single-item self-rated instrument that measured the participant's overall status on an 11-point NRS ranging from 0 (very poor) to 10 (very good).

    Time frame: Baseline

  3. Mean PSGA Score at End of Period.

    PSGA was a single-item self-rated instrument that measured the participant's overall status on an 11-point numeric rating scale (NRS) ranging from 0 (very poor) to 10 (very good).

    Time frame: End of each period, at Weeks 6 and 14

  4. Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) at Baseline.

    C-SSRS assessed whether participant experienced following: completed suicide (1), suicide attempt (2) (response of "Yes" on "actual attempt"), preparatory acts toward imminent suicidal behavior (3) ("Yes" on "preparatory acts or behavior"), suicidal ideation (4) ("Yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent), any suicidal behavior or ideation, self-injurious behavior (7) ("Yes" on "Has participant engaged in non-suicidal self-injurious behavior").

    Time frame: Baseline

  5. Number of Participants With Categorical Scores on the C-SSRS at Post-Baseline.

    C-SSRS assessed whether participant experienced following:completed suicide (1), suicide attempt (2) (response of Yes on "actual attempt"), preparatory acts toward imminent suicidal behavior (3) (Yes on "preparatory acts or behavior"), suicidal ideation (4) (Yes on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent), any suicidal behavior or ideation, self-injurious behavior (7) (Yes on "Has subject engaged in non-suicidal self-injurious behavior"). Below table indicated one participant (10141023) treated with Pregabalin reported preparatory act. However upon study unblinding it was clarified that preparatory act occurred while the participant was taking placebo. Since preparatory act was reported at first visit of Period 2, by convention statistical summaries classified this under Pregabalin treatment.

    Time frame: From Visit 3 to Visit 14

  6. Work Productivity and Activity Index-Specific Health Problem (WPAI-SHP) Questionnaire at Baseline.

    WPAI-SHP assessed work productivity and impairment. It was a participant-rated, six-item questionnaire regarding current employment, hours missed and actually worked, and degree to which a specified health problem affected work productivity and regular activities over the past 7 days. Subscale scores included percent work time missed due to the health problem; percent impairment while working due to problem; percent overall work impairment due to problem; and percent activity impairment due to problem. Each subscale score was expressed as an impairment percentage (0-100) where higher numbers indicated greater impairment and less productivity.

    Time frame: Baseline

  7. Health Utilization Assessment (Total Office Visits, Number of Hospitalizations and Number of Emergency Room Visits) at Baseline.

    The healthcare utilization assessment was used to capture healthcare utilization data at Baseline. This assessment contained 10 questions related to aspects of healthcare services.

    Time frame: Baseline

  8. Health Utilization Assessment (Time for Help no Payment) at Baseline.

    The healthcare utilization assessment was used to capture healthcare utilization data at Baseline. This assessment contained 10 questions related to aspects of healthcare services. 'Time for help no payment' refers to time other people spent without receiving payment to help with activities the patient cannot perform due to fibromyalgia.

    Time frame: Baseline

07

Results

Posted Oct 22, 2014

Participant flow

In this double blind, crossover study, a total of 197 participants were randomized to either pregabalin/placebo or placebo/pregabalin treatment sequence. Of these, 193 took at least one dose of study medication. Four randomized participants never took study medication. Randomized participants were recruited from 4 countries at 38 study centers.

Participant flow — Overall Study
MilestonePregabalin/PlaceboPlacebo/Pregabalin
Started9697
Completed7079
Not completed2618

Outcome measures

PrimaryMean NRS Pain Score at End of Period.

The daily pain diary consists of an 11-point numeric scale (NRS) ranging from 0 ("no pain") to 10 ("worst possible pain"). Participants describe their pain during the past 24 hours by choosing the appropriate number between 0 and 10. The endpoint mean pain scores for Period 1 and Period 2 are defined as the mean of the last 7 non-missing daily diary pain ratings while taking study medication in the double-blind phase during Period 1 and Period 2, respectively.

Time frame:
End of each period, at Weeks 6 and 14
Reported as:
Least squares mean · Units on a scale
Mean NRS Pain Score at End of Period.
Units on a scalePregabalinPlacebo
Mean NRS Pain Score at End of Period.4.84 ± 0.155.45 ± 0.16
Statistical analysis
  • Pregabalin vs Placebo · Mixed Models Analysis · p = 0.0001 (Primary analysis was two-sided and performed at the 0.05 significance level.) · Mean difference (final values): -0.61 · 95% CI -0.91 to -0.31Satterthwaite's approximation was used to estimate denominator degrees of freedom.
SecondaryFibromyalgia Impact Questionnaire (FIQ) Score at Baseline.

This was a 20-item participant reported outcome instrument. It contained 10 subscales, which were combined to yield a total score. The first 11 questions were related specifically to physical functioning subscale, ranging from 0 to 10. The remaining 9 questions assessed pain, fatigue, stiffness, difficulty working, and symptoms of anxiety and depression ranging from 0 to 10. The higher values indicated greater impairment. All 20 were combined to form a total score ranging from 0 to 100, provides an estimation of fibromyalgia impact with higher scores indicating more impairment. The severity categorizations for the FIQ are: less than 40 (mild), 40-60 (moderate), and above 60 (severe).

Time frame:
Baseline
Reported as:
Mean · Units on a scale
Fibromyalgia Impact Questionnaire (FIQ) Score at Baseline.
Units on a scalePregabalin/PlaceboPlacebo/Pregabalin
Total (N=96, 96)63.83 ± 11.5862.75 ± 12.51
Physical Impairment (N=96, 97)4.58 ± 2.104.44 ± 2.14
Feel Good (N=96, 97)7.78 ± 2.477.43 ± 2.32
Work Missed (N=96, 97)3.38 ± 2.883.49 ± 3.21
Do Work (N=96, 97)6.61 ± 2.036.38 ± 2.21
Pain (N=96, 96)6.98 ± 1.257.09 ± 1.32
Fatigue (N=96, 97)8.17 ± 1.378.08 ± 1.58
Rested (N=96, 97)7.90 ± 1.517.82 ± 1.96
Stiffness (N=96, 97)7.56 ± 1.767.64 ± 1.58
Anxiety (N=96, 97)5.65 ± 2.735.60 ± 2.59
Depression (N=96, 97)5.23 ± 2.644.84 ± 2.55
SecondaryFIQ Score at End of Period.

This was a 20-item participant reported outcome instrument. It contained 10 subscales, which were combined to yield a total score. The first 11 questions were related specifically to physical functioning subscale, ranging from 0 to 10. The remaining 9 questions assessed pain, fatigue, stiffness, difficulty working, and symptoms of anxiety and depression ranging from 0 to 10. The higher values indicated greater impairment. All 20 were combined to form a total score ranging from 0 to 100, provides an estimation of fibromyalgia impact with higher scores indicating more impairment. The severity categorizations for the FIQ are: less than 40 (mild), 40-60 (moderate), and above 60 (severe).

Time frame:
End of each period, at Weeks 6 and 14
Reported as:
Least squares mean · Units on a scale
FIQ Score at End of Period.
Units on a scalePregabalinPlacebo
Total (N=176, 172)43.78 ± 1.4250.38 ± 1.43
Physical impairment (N=176, 173)3.35 ± 0.173.77 ± 0.17
Feel good (N=176, 173)4.69 ± 0.235.53 ± 0.23
Work missed (N=176 , 173)2.02 ± 0.212.62 ± 0.21
Do work (N=176, 172)4.56 ± 0.205.31 ± 0.20
Pain (N=176, 173)4.91 ± 0.175.54 ± 0.17
Fatigue (N=176, 173)6.32 ± 0.196.76 ± 0.19
Rested (N=176, 173)5.64 ± 0.196.41 ± 0.19
Stiffness (N=176, 173)5.24 ± 0.195.95 ± 0.19
Anxiety (N=176, 173)3.80 ± 0.204.35 ± 0.21
Depression (N=176, 173)3.20 ± 0.204.13 ± 0.20
Statistical analysis
  • Pregabalin vs Placebo · Mixed Models Analysis · p = <0.0001 (Analysis was conducted using a two-sided test with α=0.05. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Mean difference (final values): -6.60 · 95% CI -9.33 to -3.87
  • Pregabalin vs Placebo · Mixed Models Analysis · p = 0.0078 (Analysis was conducted using a two-sided test with α=0.05. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Mean difference (final values): -0.42 · 95% CI -0.74 to -0.11
  • Pregabalin vs Placebo · Mixed Models Analysis · p = 0.0014 (Analysis was conducted using a two-sided test with α=0.05. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Mean difference (final values): -0.85 · 95% CI -1.36 to -0.33
  • Pregabalin vs Placebo · Mixed Models Analysis · p = 0.0050 (Analysis was conducted using a two-sided test with α=0.05. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Mean difference (final values): -0.59 · 95% CI -1.01 to -0.18
  • Pregabalin vs Placebo · Mixed Models Analysis · p = 0.0002 (Analysis was conducted using a two-sided test with α=0.05. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Mean difference (final values): -0.75 · 95% CI -1.14 to -0.36
  • Pregabalin vs Placebo · Mixed Models Analysis · p = 0.0006 (Analysis was conducted using a two-sided test with α=0.05. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Mean difference (final values): -0.64 · 95% CI -1.00 to -0.28
  • Pregabalin vs Placebo · Mixed Models Analysis · p = 0.0315 (Analysis was conducted using a two-sided test with α=0.05. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Mean difference (final values): -0.44 · 95% CI -0.85 to -0.04
  • Pregabalin vs Placebo · Mixed Models Analysis · p = 0.0003 (Analysis was conducted using a two-sided test with α=0.05. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Mean difference (final values): -0.76 · 95% CI -1.17 to -0.35
  • Pregabalin vs Placebo · Mixed Models Analysis · p = 0.0007 (Analysis was conducted using a two-sided test with α=0.05. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Mean difference (final values): -0.71 · 95% CI -1.11 to -0.31
  • Pregabalin vs Placebo · Mixed Models Analysis · p = 0.0048 (Analysis was conducted using a two-sided test with α=0.05. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Mean difference (final values): -0.55 · 95% CI -0.93 to -0.17
  • Pregabalin vs Placebo · Mixed Models Analysis · p = <0.0001 (Analysis was conducted using a two-sided test with α=0.05. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Mean difference (final values): -0.92 · 95% CI -1.32 to -0.53
SecondaryPatient Global Impression of Change (PGIC) at the End of Period 1.

PGIC: participant rated instrument to measure participant's change in overall status on a 7-point scale; range from 1 (very much improved) to 7 (very much worse).

Time frame:
End of Period 1 at Week 6
Reported as:
Number · Percentage of participants
Patient Global Impression of Change (PGIC) at the End of Period 1.
Percentage of participantsPregabalinPlacebo
Very much improved10.84.3
Much improved35.525.8
Minimally improved28.040.9
No change17.221.5
Minimally worse4.36.5
Much worse3.21.1
Very much worse1.10
Statistical analysis
  • Pregabalin vs Placebo · Cochran-Mantel-Haenszel · p = 0.0637 (This analysis was conducted using a two-sided test with α=0.05. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.)
Other pre-specifiedPGIC at the End of Period 2.

PGIC: participant rated instrument to measure participant's change in overall status on a 7-point scale; range from 1 (very much improved) to 7 (very much worse). Because of the crossover design and PGIC recall period (since starting study medication), the Period 1 PGIC data were felt to provide the clearest comparison across treatments, whereas Period 2 PGIC data were felt to have a more complex interpretation. Thus PGIC at End of Period 2 was separately analyzed from PGIC at End of Period 1.

Time frame:
End of Period 2 at Week 14
Reported as:
Number · Percentage of Participants
PGIC at the End of Period 2.
Percentage of ParticipantsPregabalinPlacebo
Very much improved18.38.6
Much improved34.125.9
Minimally improved28.038.3
No change11.014.8
Minimally worse6.18.6
Much worse1.22.5
Very much worse1.21.2
Statistical analysis
  • Pregabalin vs Placebo · Cochran-Mantel-Haenszel · p = 0.1160 (This analysis was conducted using a two-sided test with α=0.05. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.)
SecondaryPercentage of Participants With >=30% and >=50% Pain Reduction Based on Daily Pain Diary.

Participant with at least a 30% reduction in mean pain score from baseline (at randomization) to the endpoint at the end of each period (Visits 6 and 12) is considered a 30% responder, for the respective period. Similarly, a subject with at least a 50% reduction in mean pain score from baseline (at randomization) to the endpoint at the end of each period (Visits 6 and 12) is considered a 50% responder, for the respective period.

Time frame:
Visits 2, 6, and 12
Reported as:
Number · Percentage of participants
Percentage of Participants With >=30% and >=50% Pain Reduction Based on Daily Pain Diary.
Percentage of participantsPregabalinPlacebo
30% Responders45.327.7
50% Responders26.015.8
Statistical analysis
  • Pregabalin vs Placebo · Regression, Logistic · p = 0.0007 (This secondary analyses was conducted using a two-sided test with α=0.05. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.)
  • Pregabalin vs Placebo · Regression, Logistic · p = 0.0205 (This secondary analyses was conducted using a two-sided test with α=0.05. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.)
SecondarySubjective Sleep Questionnaire - Mean Sleep Quality at End of Period.

Subjective Sleep Questionnaire included 5 items: participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (NRS) for the previous night. Subjective rating of quality of sleep during the past night was done by selecting a number between 0 (very poor) and 10 (excellent). Mean sleep quality was calculated as the mean of the last seven days, the potential range of responses was therefore 0-10.

Time frame:
End of each period, at Weeks 6 and 14
Reported as:
Least squares mean · Units on a scale
Subjective Sleep Questionnaire - Mean Sleep Quality at End of Period.
Units on a scalePregabalinPlacebo
Subjective Sleep Questionnaire - Mean Sleep Quality at End of Period.6.15 ± 0.145.57 ± 0.14
Statistical analysis
  • Pregabalin vs Placebo · Mixed Models Analysis · p = <0.0001 (This was done using a two-sided test with α=0.05. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Mean difference (final values): 0.57 · 95% CI 0.31 to 0.84
SecondarySubjective Sleep Questionnaire - Mean Subjective Wake After Sleep Onset at End of Period.

Subjective Sleep Questionnaire included, participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (numeric rating scale) for the previous night. Subjective wake after sleep onset was the subjective estimate of the total amount of time the participant was awake after initial sleep onset until final awakening.

Time frame:
End of each period, at Weeks 6 and 14
Reported as:
Least squares mean · Minutes
Subjective Sleep Questionnaire - Mean Subjective Wake After Sleep Onset at End of Period.
MinutesPregabalinPlacebo
Subjective Sleep Questionnaire - Mean Subjective Wake After Sleep Onset at End of Period.33.38 ± 2.7341.18 ± 2.76
Statistical analysis
  • Pregabalin vs Placebo · Mixed Models Analysis · p = 0.0018 (This was done using a two-sided test with α=0.05. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Mean difference (final values): -7.81 · 95% CI -12.66 to -2.96
SecondarySubjective Sleep Questionnaire - Mean Latency to Sleep Onset at End of Period.

Subjective Sleep Questionnaire included, participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (numeric rating scale) for the previous night. Subjective latency to sleep onset was the subjective estimate of the amount of time to fall asleep after lights out.

Time frame:
End of each period, at Weeks 6 and 14
Reported as:
Least squares mean · Minutes
Subjective Sleep Questionnaire - Mean Latency to Sleep Onset at End of Period.
MinutesPregabalinPlacebo
Subjective Sleep Questionnaire - Mean Latency to Sleep Onset at End of Period.33.54 ± 2.6839.33 ± 2.71
Statistical analysis
  • Pregabalin vs Placebo · Mixed Models Analysis · p = 0.0117 (This was done using a two-sided test with α=0.05. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Mean difference (final values): -5.80 · 95% CI -10.29 to -1.31
SecondarySubjective Sleep Questionnaire - Mean Subjective Total Sleep Time at End of Period.

Subjective Sleep Questionnaire included, participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (numeric rating scale) for the previous night. Subjective total sleep time was the subjective estimate of the total amount of time the participant was asleep after lights out until final awakening.

Time frame:
End of each period, at Weeks 6 and 14
Reported as:
Least squares mean · Minutes
Subjective Sleep Questionnaire - Mean Subjective Total Sleep Time at End of Period.
MinutesPregabalinPlacebo
Subjective Sleep Questionnaire - Mean Subjective Total Sleep Time at End of Period.422.98 ± 5.42414.63 ± 5.48
Statistical analysis
  • Pregabalin vs Placebo · Mixed Models Analysis · p = 0.0511 (This was done using a two-sided test with α=0.05. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Mean difference (final values): 8.35 · 95% CI -0.04 to 16.74
SecondarySubjective Sleep Questionnaire - Parameter Estimates for Subjective Number of Awakenings Per Night After Sleep Onset at End of Period.

Subjective Sleep Questionnaire included, participants report latency (how long it took them to fall asleep), how many hours they slept, the number of times they woke up, the total wake time after sleep onset, and then rate the quality of their sleep (numeric rating scale) for the previous night. Subjective number of awakenings after sleep onset was the subjective estimate of the total number of times the participant awakened during the night until final awakening.

Time frame:
End of each period, at Weeks 6 and 14
Reported as:
Least squares mean · Number of times awakened
Subjective Sleep Questionnaire - Parameter Estimates for Subjective Number of Awakenings Per Night After Sleep Onset at End of Period.
Number of times awakenedPregabalinPlacebo
Subjective Sleep Questionnaire - Parameter Estimates for Subjective Number of Awakenings Per Night After Sleep Onset at End of Period.0.48 ± 0.070.61 ± 0.07
Statistical analysis
  • Pregabalin vs Placebo · Mixed Models Analysis · p = 0.1139 (This was done using a two-sided test with α=0.05. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Mean difference (final values): -0.13 · 95% CI -0.29 to 0.03
SecondaryHospital Anxiety and Depression Scale (HADS) at Baseline.

HADS: participant rated questionnaire with 2 subscales. HADS-A (anxiety) assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D (depression) assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.

Time frame:
Baseline
Reported as:
Mean · Units on a scale
Hospital Anxiety and Depression Scale (HADS) at Baseline.
Units on a scalePregabalin/PlaceboPlacebo/Pregabalin
HADS-A (anxiety)8.67 ± 3.957.97 ± 3.77
HADS-D (depression)8.34 ± 3.597.73 ± 3.64
SecondaryHADS at End of Period.

HADS: participant rated questionnaire with 2 subscales. HADS-A (anxiety) assesses state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks); HADS-D (depression) assesses state of lost interest and diminished pleasure response (lowering of hedonic tone). Each subscale comprised of 7 items with range 0 (no presence of anxiety or depression) to 3 (severe feeling of anxiety or depression). Total score 0 to 21 for each subscale; higher score indicates greater severity of anxiety and depression symptoms.

Time frame:
End of each period, at Weeks 6 and 14
Reported as:
Least squares mean · Units on a scale
HADS at End of Period.
Units on a scalePregabalinPlacebo
HADS-A (anxiety)6.01 ± 0.286.96 ± 0.28
HADS-D (depression)6.17 ± 0.317.05 ± 0.31
Statistical analysis
  • Pregabalin vs Placebo · Mixed Models Analysis · p = <0.0001 (Two-sided test with α=0.05 was used. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Mean difference (final values): -0.95 · 95% CI -1.40 to -0.50
  • Pregabalin vs Placebo · Mixed Models Analysis · p = 0.0005 (Two-sided test with α=0.05 was used. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Mean difference (final values): -0.88 · 95% CI -1.37 to -0.39
SecondaryMean EuroQoL 5-Dimensions (EQ-5D) Score at Baseline.

EQ-5D is a standardized, participant-administered measure of health outcome. It provides a descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), using 3 levels (no, moderate, or extreme problems) and a single index value characterizing current health status using a 100-point visual analog scale (0=worst, 100=best). EQ-5D summary index is obtained with a formula that weights each level of the dimensions. The index-based score is interpreted along a continuum of 0 (death) to 1 (perfect health).

Time frame:
Baseline
Reported as:
Mean · Units on a scale
Mean EuroQoL 5-Dimensions (EQ-5D) Score at Baseline.
Units on a scalePregabalin/PlaceboPlacebo/Pregabalin
Mean EuroQoL 5-Dimensions (EQ-5D) Score at Baseline.0.40 ± 0.310.37 ± 0.33
SecondaryEQ-5D Score at End of Period.

EQ-5D is a standardized, participant-administered measure of health outcome. It provides a descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), using 3 levels (no, moderate, or extreme problems) and a single index value characterizing current health status using a 100-point visual analog scale (0=worst, 100=best). EQ-5D summary index is obtained with a formula that weights each level of the dimensions. The index-based score is interpreted along a continuum of 0 (death) to 1 (perfect health).

Time frame:
End of each period, at Weeks 6 and 14
Reported as:
Least squares mean · Units on a scale
EQ-5D Score at End of Period.
Units on a scalePregabalinPlacebo
EQ-5D Score at End of Period.0.58 ± 0.020.56 ± 0.02
Statistical analysis
  • Pregabalin vs Placebo · Mixed Models Analysis · p = 0.3854 (Two-sided test with α=0.05 was used. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Mean difference (final values): 0.02 · 95% CI -0.02 to 0.06
Other pre-specifiedMean Patient Static Global Assessment (PSGA) Score at Baseline.

PSGA was a single-item self-rated instrument that measured the participant's overall status on an 11-point NRS ranging from 0 (very poor) to 10 (very good).

Time frame:
Baseline
Reported as:
Mean · Units on a scale
Mean Patient Static Global Assessment (PSGA) Score at Baseline.
Units on a scalePregabalin/PlaceboPlacebo/Pregabalin
Mean Patient Static Global Assessment (PSGA) Score at Baseline.4.35 ± 2.044.46 ± 1.92
Other pre-specifiedMean PSGA Score at End of Period.

PSGA was a single-item self-rated instrument that measured the participant's overall status on an 11-point numeric rating scale (NRS) ranging from 0 (very poor) to 10 (very good).

Time frame:
End of each period, at Weeks 6 and 14
Reported as:
Least squares mean · Units on a scale
Mean PSGA Score at End of Period.
Units on a scalePregabalinPlacebo
Mean PSGA Score at End of Period.5.83 ± 0.175.27 ± 0.17
Statistical analysis
  • Pregabalin vs Placebo · Mixed Models Analysis · p = 0.0085 (Two-sided test with α=0.05 was used. No corrections to alpha to control for potential inflation of Type I error resulting from multiple comparisons were made.) · Mean difference (final values): 0.55 · 95% CI 0.14 to 0.97
Other pre-specifiedNumber of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) at Baseline.

C-SSRS assessed whether participant experienced following: completed suicide (1), suicide attempt (2) (response of "Yes" on "actual attempt"), preparatory acts toward imminent suicidal behavior (3) ("Yes" on "preparatory acts or behavior"), suicidal ideation (4) ("Yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent), any suicidal behavior or ideation, self-injurious behavior (7) ("Yes" on "Has participant engaged in non-suicidal self-injurious behavior").

Time frame:
Baseline
Reported as:
Number · Participants
Number of Participants With Categorical Scores on the Columbia Suicide Severity Rating Scale (C-SSRS) at Baseline.
ParticipantsPregabalin/PlaceboPlacebo/Pregabalin
Wish to be Dead31
Non-Specific Thoughts01
Without Intent to Act00
Some Intent to Act00
Specific Plan and Intent00
Actual Attempt00
Non-Suicidal Self-Injurious Behavior00
Interrupted Attempt00
Aborted Attempt00
Preparatory Acts or Behavior00
Suicidal Behavior Present00
Completed Suicide00
Other pre-specifiedNumber of Participants With Categorical Scores on the C-SSRS at Post-Baseline.

C-SSRS assessed whether participant experienced following:completed suicide (1), suicide attempt (2) (response of Yes on "actual attempt"), preparatory acts toward imminent suicidal behavior (3) (Yes on "preparatory acts or behavior"), suicidal ideation (4) (Yes on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act or some intent to act, without specific plan or with specific plan and intent), any suicidal behavior or ideation, self-injurious behavior (7) (Yes on "Has subject engaged in non-suicidal self-injurious behavior"). Below table indicated one participant (10141023) treated with Pregabalin reported preparatory act. However upon study unblinding it was clarified that preparatory act occurred while the participant was taking placebo. Since preparatory act was reported at first visit of Period 2, by convention statistical summaries classified this under Pregabalin treatment.

Time frame:
From Visit 3 to Visit 14
Reported as:
Number · Participants
Number of Participants With Categorical Scores on the C-SSRS at Post-Baseline.
ParticipantsPregabalinPlacebo
Wish to be Dead108
Non-Specific Thoughts31
Without Intent to Act20
Some Intent to Act00
Specific Plan and Intent00
Actual Attempt00
Non-Suicidal Self-Injurious Behavior00
Interrupted Attempt00
Aborted Attempt00
Preparatory Acts or Behavior10
Suicidal Behavior Present10
Completed Suicide00
Other pre-specifiedWork Productivity and Activity Index-Specific Health Problem (WPAI-SHP) Questionnaire at Baseline.

WPAI-SHP assessed work productivity and impairment. It was a participant-rated, six-item questionnaire regarding current employment, hours missed and actually worked, and degree to which a specified health problem affected work productivity and regular activities over the past 7 days. Subscale scores included percent work time missed due to the health problem; percent impairment while working due to problem; percent overall work impairment due to problem; and percent activity impairment due to problem. Each subscale score was expressed as an impairment percentage (0-100) where higher numbers indicated greater impairment and less productivity.

Time frame:
Baseline
Reported as:
Mean · Units on a scale
Work Productivity and Activity Index-Specific Health Problem (WPAI-SHP) Questionnaire at Baseline.
Units on a scaleAll Participants
Percent Absenteeism (N= 86)15.22 ± 25.36
Percent Presenteeism (N= 83)53.98 ± 21.52
Percent Overall Work Impairment (N= 82)57.96 ± 23.42
Percent Activity Impairment (N=193)64.97 ± 18.77
Other pre-specifiedHealth Utilization Assessment (Total Office Visits, Number of Hospitalizations and Number of Emergency Room Visits) at Baseline.

The healthcare utilization assessment was used to capture healthcare utilization data at Baseline. This assessment contained 10 questions related to aspects of healthcare services.

Time frame:
Baseline
Reported as:
Mean · Visits
Health Utilization Assessment (Total Office Visits, Number of Hospitalizations and Number of Emergency Room Visits) at Baseline.
VisitsAll Participants
Total office visits (N= 193)5.01 ± 6.6
Number of hospitalizations (N= 0)NA ± NA
Number of emergency room visits (N= 12)1.83 ± 1.0
Other pre-specifiedHealth Utilization Assessment (Time for Help no Payment) at Baseline.

The healthcare utilization assessment was used to capture healthcare utilization data at Baseline. This assessment contained 10 questions related to aspects of healthcare services. 'Time for help no payment' refers to time other people spent without receiving payment to help with activities the patient cannot perform due to fibromyalgia.

Time frame:
Baseline
Reported as:
Mean · Hours
Health Utilization Assessment (Time for Help no Payment) at Baseline.
HoursAll Participants
Health Utilization Assessment (Time for Help no Payment) at Baseline.50.37 ± 98.1

Adverse events

Collected over Up to Week 16. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin—3/181 (1.7%)139/181 (76.8%)
Placebo—1/177 (0.6%)106/177 (59.9%)
Most frequent serious events
Most frequent serious events
EventPregabalinPlacebo
Brain neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1811/177
Pain in extremityMusculoskeletal and connective tissue disorders1/1810/177
AnxietyPsychiatric disorders1/1810/177
DetoxificationSurgical and medical procedures1/1810/177
Most frequent other events
Showing 10 of 194
Most frequent other events
EventPregabalinPlacebo
DizzinessNervous system disorders51/18112/177
SomnolenceNervous system disorders36/1818/177
ConstipationGastrointestinal disorders19/1814/177
HeadacheNervous system disorders14/18117/177
NauseaGastrointestinal disorders17/18112/177
DiarrhoeaGastrointestinal disorders16/1817/177
Weight increasedInvestigations16/1813/177
InsomniaPsychiatric disorders13/1811/177
Dry mouthGastrointestinal disorders12/1811/177
FatigueGeneral disorders12/1818/177

Baseline characteristics

Age, Customized
Age, Customized(Participants)Pregabalin/PlaceboPlacebo/PregabalinTotal
< 18 Years000
18-44 Years222951
45-64 Years6960129
>= 65 Years5813
Sex: Female, Male
Sex: Female, Male(Participants)Pregabalin/PlaceboPlacebo/PregabalinTotal
Female8793180
Male9413
08

Study locations

37 sites
  • Genova Clinical Research
    Tucson, Arizona 85704, United States
  • SDS Clinical Trials
    Orange, California 92868, United States
  • Research Across America
    Santa Ana, California 92705, United States
  • Innovative Research of West Florida, Inc.
    Clearwater, Florida 33756, United States
  • Florida Medical Center & Research, Inc.
    Coral Gables, Florida 33134, United States
  • Meridien Research
    Tampa, Florida 33606, United States
  • Medical Research and Health Education Foundation, Inc.
    Columbus, Georgia 31909, United States
  • Heartland Research Associates, LLC
    Wichita, Kansas 67207, United States
  • Central Kentucky Research Associates, Inc.
    Lexington, Kentucky 40509, United States
  • Boston Clinical Trials
    Boston, Massachusetts 02131, United States
  • Michigan Head Pain and Neurological Institute
    Ann Arbor, Michigan 48104, United States
  • Quality Clinical Research, Inc.
    Omaha, Nebraska 68114, United States
  • Social Psychiatry Research Institute
    Brooklyn, New York 11235, United States
  • University of Cincinnati
    Cincinnati, Ohio 45219, United States
  • Radiant Research, Inc.
    Columbus, Ohio 43212, United States
  • Midwest Clinical Research Center
    Dayton, Ohio 45417, United States
  • Sunstone Medical Research, LLC
    Medford, Oregon 97504, United States
  • Behavioral Medicine Center
    Wyomissing, Pennsylvania 19610, United States
  • Clinical Research Center of Reading, LLP
    Wyomissing, Pennsylvania 19610, United States
  • Coastal Medical
    East Greenwich, Rhode Island 02818, United States
  • Omega Medical Research
    Warwick, Rhode Island 02886, United States
  • Coastal Carolina Research Center
    Mount Pleasant, South Carolina 29464, United States
  • FutureSearch Trials of Neurology
    Austin, Texas 78731, United States
  • Fatigue Consultation Clinic
    Salt Lake City, Utah 84102, United States
  • Lifetree Clinical Research, LC
    Salt Lake City, Utah 84106, United States
  • Charlottesville Medical Research
    Charlottesville, Virginia 22911, United States
  • Dr. Alexander McIntyre Inc.
    Penticton, British Columbia V2A 4M4, Canada
  • Canadian Centre for Clinical Trials
    Thornhill, Ontario L4J 1W3, Canada
  • Diex Research Sherbrooke Inc.
    Sherbrooke, Quebec J1H 1Z1, Canada
  • Azienda Ospedaliera Luigi Sacco - Polo Universitario
    Milano, 20157, Italy
  • Università degli Studi di Roma "La Sapienza"
    Roma, 00161, Italy
  • Hospital de lˊEsperança
    Barcelona, 08024, Spain
  • Instituto Universitario USP Dexeus
    Barcelona, 08028, Spain
  • Servicio de Reumatologia,Institut Ferran de Reumatologia-Clinica CIMA
    Barcelona, 08034, Spain
  • Hospital Clínic de Barcelona
    Barcelona, 08036, Spain
  • Hospital General Universitario de Guadalajara
    Guadalajara, 19002, Spain
  • Hospital General Universitario Gregorio Marañon
    Madrid, 28028, Spain
09

References and documents

Publications

  • Bateman L, Sarzi-Puttini P, Burbridge CL, Landen JW, Masters ET, Bhadra Brown P, Scavone JM, Emir B, Vissing RS, Clair AG, Pauer LR. Burden of illness in fibromyalgia patients with comorbid depression. Clin Exp Rheumatol. 2016 Mar-Apr;34(2 Suppl 96):S106-13. Epub 2016 Mar 10. PubMed 27057659 ↗
  • Arnold LM, Sarzi-Puttini P, Arsenault P, Khan T, Bhadra Brown P, Clair A, Scavone JM, Driscoll J, Landen J, Pauer L. Efficacy and Safety of Pregabalin in Patients with Fibromyalgia and Comorbid Depression Taking Concurrent Antidepressant Medication: A Randomized, Placebo-controlled Study. J Rheumatol. 2015 Jul;42(7):1237-44. doi: 10.3899/jrheum.141196. Epub 2015 Jun 1. PubMed 26034150 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2011
First posted
Sep 12, 2011
Start
Oct 2011
Primary completionActual
Jul 2013
CompletionActual
Jul 2013
Results first posted
Oct 22, 2014
Last update
Jan 22, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01432236
Responsible party
Sponsor
First posted
Sep 12, 2011
Start date
Oct 2011
Primary completion
Jul 2013
Completion
Jul 2013
Results posted
Oct 22, 2014
Last update
Jan 22, 2021

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion